Stock Analysis

High Insider Ownership Growth Companies On Euronext Paris May 2024

ENXTPA:LSS
Source: Shutterstock

As of May 2024, the French market, like many across Europe, has been grappling with fluctuating indices and cautious investor sentiment amid discussions about interest rate movements. In such a landscape, growth companies with high insider ownership on Euronext Paris stand out as potentially resilient investments due to their leaders' vested interests aligning closely with shareholder values.

Top 10 Growth Companies With High Insider Ownership In France

NameInsider OwnershipEarnings Growth
VusionGroup (ENXTPA:VU)13.5%24.4%
Groupe OKwind Société anonyme (ENXTPA:ALOKW)24.8%30.6%
WALLIX GROUP (ENXTPA:ALLIX)19.8%101.4%
La Française de l'Energie (ENXTPA:FDE)20.1%37.7%
Adocia (ENXTPA:ADOC)12.4%104.5%
OSE Immunotherapeutics (ENXTPA:OSE)24.9%92.9%
Icape Holding (ENXTPA:ALICA)30.2%26.1%
Arcure (ENXTPA:ALCUR)21.4%41.7%
Munic (ENXTPA:ALMUN)29.2%150%
MedinCell (ENXTPA:MEDCL)16.4%68.8%

Click here to see the full list of 21 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Believe (ENXTPA:BLV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Believe S.A. operates as a digital music service provider for independent labels and artists across various regions including France, Germany, Europe, the Americas, Asia, Oceania, and the Pacific, with a market capitalization of approximately €1.49 billion.

Operations: The company generates revenue through two primary segments: Premium Solutions at €825.12 million and Automated Solutions at €55.19 million.

Insider Ownership: 10.9%

Earnings Growth Forecast: 74.2% p.a.

Believe S.A. is trading significantly below its estimated fair value, presenting a potentially attractive entry point despite slower-than-desired revenue growth at 14% per year. Earnings are expected to surge, with forecasts predicting a substantial increase. The company's return on equity is projected to remain modest in the coming years. Recent events include failed acquisition talks with Warner Music and ongoing discussions with a consortium led by insiders, highlighting high insider involvement but also potential instability in ownership structure.

ENXTPA:BLV Earnings and Revenue Growth as at May 2024
ENXTPA:BLV Earnings and Revenue Growth as at May 2024

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions across fashion, automotive, and furniture sectors with a market capitalization of approximately €1.23 billion.

Operations: The company generates revenue primarily from the Americas and Asia-Pacific regions, totaling approximately €170.33 million and €110.28 million respectively.

Insider Ownership: 19.6%

Earnings Growth Forecast: 28.6% p.a.

Lectra SA, a French company with significant insider ownership, reported a slight decline in net income to €7.17 million from €7.63 million year-over-year, despite an increase in sales to €129.56 million for Q1 2024. The company's earnings are expected to grow by 28.6% annually over the next three years, outpacing the French market's forecast of 10.9%. However, its projected return on equity is relatively low at 13.3%, indicating potential challenges in achieving higher profitability levels.

ENXTPA:LSS Earnings and Revenue Growth as at May 2024
ENXTPA:LSS Earnings and Revenue Growth as at May 2024

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €440.48 million.

Operations: The company generates its revenue primarily from the pharmaceutical sector, totaling €14.13 million.

Insider Ownership: 16.4%

Earnings Growth Forecast: 68.8% p.a.

MedinCell, a French growth company with substantial insider ownership, is navigating mixed outcomes in its recent clinical trials. While the Phase 3 trial for F14 did not meet its primary endpoint, it showed numerical improvements in secondary measures and a consistent safety profile. This positions MedinCell to explore alternative approval pathways. Financially, MedinCell is set to grow significantly with projected annual revenue increases of 40.1% and anticipated profitability within three years, despite a highly volatile share price and recent shareholder dilution.

ENXTPA:MEDCL Earnings and Revenue Growth as at May 2024
ENXTPA:MEDCL Earnings and Revenue Growth as at May 2024

Turning Ideas Into Actions

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com